STOCK SCREENER · NATURAL LANGUAGE + FILTERS · FREE

Stock screener — ask Axel or pick filters.

Two ways to screen: (1) fill the form below for precise control, or (2) chat with Axel: "sugar sector companies with revenue over ₹100 Cr and P/E under 18" — Axel translates to filters, runs the screener, returns matches.

CURATED PRESETS · ONE-CLICK SCREENS

Hand-tuned screens with live results. Each preset links to a dedicated page with commentary, refinement, and Axel narration.

High ROCE · low debt →

Indian companies delivering ROCE above 20% with debt-to-equity below 0.5 — quality compounders that make money without leverage. Filtered live from NSE/BSE XBRL filings. Free, no signup.

Value large-caps →

Large-cap Indian stocks (market cap > ₹50,000 Cr) trading under P/E 15 with ROE above 15% — the classic value-at-scale screen. Data from NSE/BSE public filings, refreshed daily.

Debt-free growth →

Indian stocks with debt-to-equity below 0.1 and revenue YoY growth above 20% — growth compounders that fund expansion from internal accruals, not borrowings. Live from XBRL filings.

Small-cap growth →

Small-cap Indian companies (₹500–5,000 Cr market cap) growing revenue above 25% YoY with positive profit growth. High-risk, high-potential universe — filter before research.

High ROE compounders →

Indian stocks with ROE above 18% and positive revenue growth — the Buffett-style quality-compounder screen. Applied to the full NSE/BSE universe, refreshed daily.

Mid-cap value →

Mid-cap Indian stocks (₹5,000–50,000 Cr) trading below P/E 20 with ROE above 15% — the sweet-spot universe where large-cap stability meets small-cap growth without either's extremes.

Consistent profit growers →

Indian stocks with profit YoY growth above 25% and revenue growth above 15% — operational-leverage compounders where the bottom line grows faster than the top.

Affordable quality →

Classic GARP (growth at reasonable price) screen for Indian equities — ROE above 15%, P/E under 20, debt-to-equity below 0.75. Finds the unsexy-but-solid that neither value nor growth camps fight over.

50 MATCHED

ROE ≥ 20% · D/E ≤ 0.5

Symbol	Sector	Mkt cap (Cr)	P/E	ROE %	ROCE %	D/E	Rev YoY
TCS	Information Technology	9,33,322	19.0	48.4%	—	0.10	+9.6%
INFY	Information Technology	5,31,162	18.3	32.7%	—	0.10	+3.2%
HINDUNILVR	Consumer Goods	5,24,387	51.9	20.7%	—	0.04	+3.9%
HCLTECH	Information Technology	3,86,448	23.5	23.2%	—	0.10	+7.4%
ITC	Consumer Goods	3,82,149	18.8	28.7%	—	0.01	+6.7%
BEL	Defence	3,36,177	56.5	27.6%	—	0.00	+17.9%
HAL	Defence	2,90,549	32.7	24.0%	—	0.00	+10.7%
COALINDIA	Metals & Mining	2,72,239	9.1	28.3%	—	0.13	-4.8%
NESTLEIND	Consumer Goods	2,48,058	75.8	73.8%	—	0.11	+18.6%
EICHERMOT	Automobile	1,98,686	37.2	24.2%	—	0.02	+22.9%
HYUNDAI	Other	1,53,294	26.5	32.9%	—	0.05	—
ABB	Capital Goods	1,51,693	90.9	22.4%	—	0.01	+5.7%
TRENT	Retail	1,50,826	92.2	26.8%	—	0.38	+14.8%
BSE	Financial Services	1,42,868	66.4	34.2%	—	0.00	+100.0%
CUMMINSIND	Capital Goods	1,42,614	63.7	28.3%	—	0.00	+16.0%
TORNTPHARM	Healthcare	1,41,849	62.3	27.0%	—	0.33	+17.6%
PIDILITIND	Chemicals	1,41,522	62.0	23.9%	—	0.04	+10.1%
LTM	Other	1,39,795	29.4	21.0%	—	0.10	+11.6%
LTIM	Information Technology	1,33,516	28.1	21.0%	—	0.10	+11.6%
POLYCAB	Capital Goods	1,23,852	47.2	26.0%	—	0.02	+24.2%
GROWW	Other	1,20,117	70.3	22.4%	—	0.05	—
ENRIN	Other	1,09,573	92.6	27.0%	—	0.03	—
GVT&D	Other	1,08,507	101.4	51.3%	—	0.01	+35.5%
LGEINDIA	Other	1,08,203	62.0	25.4%	—	0.07	-6.4%
HEROMOTOCO	Automobile	1,05,697	19.4	25.9%	—	0.03	+21.7%
UNITDSPR	Consumer Goods	95,122	54.0	20.5%	—	0.05	+7.6%
PERSISTENT	Information Technology	85,452	49.5	25.0%	—	0.06	+21.6%
OFSS	Information Technology	69,476	28.5	33.5%	—	0.01	+7.4%
DIXON	Capital Goods	68,387	41.1	36.5%	—	0.30	+119.7%
APLAPOLLO	Metals	58,644	49.9	25.5%	—	0.15	+14.2%
COLPAL	Consumer Goods	57,906	43.6	84.0%	—	0.04	+1.7%
ABBOTINDIA	Other	54,547	35.8	38.0%	—	0.04	+9.6%
HINDCOPPER	Other	54,057	81.7	22.3%	—	0.05	—
APARINDS	Capital Goods	46,696	48.0	20.1%	—	0.14	+15.0%
IRCTC	Railways	45,220	31.8	33.4%	—	0.02	+9.5%
GLAXO	Other	41,279	40.4	59.9%	—	0.02	+8.6%
AIIL	Other	39,442	10.9	22.3%	—	0.20	—
AJANTPHARM	Healthcare	35,168	34.7	23.5%	—	0.06	+10.4%
3MINDIA	Other	35,158	92.9	23.5%	—	0.06	+6.1%
GODFRYPHLP	Other	33,848	26.1	22.3%	—	0.03	+1.1%
CRISIL	Other	31,534	41.1	27.4%	—	0.10	+11.9%
ABSLAMC	Other	30,790	30.3	28.5%	—	0.02	+21.0%
ANANDRATHI	Other	30,692	78.3	46.7%	—	0.08	+22.3%
GRSE	Defence	30,574	44.3	30.0%	—	0.01	+41.3%
HEXT	Other	29,797	22.0	23.5%	—	0.11	+14.7%
CDSL	Financial Services	28,806	60.3	27.4%	—	0.00	+33.2%
MSUMI	Other	25,989	41.7	33.7%	—	0.14	+25.6%
GILLETTE	Other	25,703	48.2	45.9%	—	0.00	+4.0%
NBCC	Other	25,196	38.6	24.4%	—	0.00	+9.5%
IKS	Other	24,040	36.8	29.1%	—	0.34	—

How this screener works

Every fundamental number below comes from public NSE / BSE XBRL quarterly + annual filings. We parse IND-AS taxonomy filings weekly, normalise to our Supabase schema, and compute valuation ratios daily against the live close price. Same source Screener.in uses — we're just presenting it alongside Axel and the 100+ other tools on this platform.

Current coverage:NIFTY 50 + Next 50 constituents — growing weekly as our ingestion pipeline expands to the full ~2,000 listed companies. If a stock you searched isn't here yet, it will appear after the next cron cycle (Sundays 02:00 IST).

Data freshness: ratios recompute daily at market close. Financials update within 48 hours of a quarterly filing.

ASK AXEL

Chat-first screening beats filter-form screening

Describe what you want in one line. Axel translates to precise filters, runs the screener, explains its interpretation so you can refine. Research framing only — not a buy/sell recommendation.

Ask Axel free

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Screener results are a data-driven filter of publicly-disclosed financials from NSE + BSE XBRL filings. Not investment advice, not a buy/sell recommendation. Filters reflect the metrics you've specified; they do not encapsulate company-specific risks, management quality, sector cyclicality, or forward prospects. Always combine screener output with qualitative analysis before making any investment decision.